Paxlovid

(Nirmatrelvir)

ApprovedSmall molecule

Paxlovid is a small molecule that works as a SARS Coronavirus 3c-Like Proteinase Inhibitor.[2] It is being used across 7 indications, with its most advanced program in Approved.[1]

Paxlovid is one of 182 small molecule programs targeting Long COVID-19. It is currently in Approved.

Indications

Total Trials

Active Trials

181

Competitors

Pipeline

Status by Indication[3][1]

Indication

Long COVID-19Active, not recruiting

Kidney DiseaseActive, not recruiting

PneumoniaActive, not recruiting

Liver DiseaseActive, not recruiting

COVID-19Active, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Long COVID-19Phase 2

Active, not recruiting

Kidney DiseasePhase 1

Active, not recruiting

PneumoniaPhase 3

Active, not recruiting

Liver DiseasePhase 1

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Chronic Kidney DiseaseApproved

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Paxlovid

Pfizer

Approved

22 2

Spikevax

Moderna

Preclinical

21 3

Bnt162b2

BioNTech

Preclinical

29 4

COVID-19 Vaccine

Moderna

Preclinical

27 5

Biaxin

AbbVie

Preclinical

2 6

Stivarga

Bayer

Preclinical

1 7

Aimovig

Amgen

Preclinical

1 8

Aldactone

Pfizer

Preclinical

1 9

Nexavar

Bayer

Preclinical

1 10

Singulair

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Recruiting

COVID-19

NCT05261139

Q1 2027

Post-ApprovalRecruiting

COVID-19

NCT06792214

Phase 2Recruiting

COVID-19

NCT05041907

Q2 2027

Phase 3Active, not recruiting

Long COVID-19

NCT05852873

Q1 2028

Phase 3Recruiting

Pneumonia

NCT02735707

Clinical

Trials by Indication[1]

COVID-1922 trials

A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir

Completed· Pfizer logo

Pfizer·Phase 2·NCT05567952·436 enrolled

The Safety of Paxlovid in Hemodialysis Patients With Covid-19

Completed·RRenJi Hospital·Phase 4·NCT05366192·18 enrolled

A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.

Completed· Pfizer logo

Pfizer··NCT06291831·3,011 enrolled

Show 19 more trials

A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe

Completed· Pfizer logo

Pfizer··NCT07072793·131,005 enrolled

A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia

Completed· Pfizer logo

Pfizer··NCT06016556·250 enrolled

A Study to Learn About the Patients With COVID-19 Prescribed Paxlovid in Morocco

Withdrawn· Pfizer logo

Pfizer··NCT05997485

Saliva PCR in Pregnant Women with COVID-19

Completed·NNational Cheng-Kung University Hospital··NCT06735300·37 enrolled

Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial

Recruiting·MMount Sinai Hospital, Canada·Phase 4·NCT06792214·118 enrolled

A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19

Not yet recruiting· Pfizer logo

Pfizer··NCT07089680·1,200 enrolled

A Study of Efficacy and Safety of Azvudine vs. Nirmatrelvir-Ritonavir in the Treatment of COVID-19 Infection

Unknown status·SShandong Provincial Hospital·Phase 4·NCT05697055·410 enrolled

A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19

Completed· Pfizer logo

Pfizer··NCT05263908·3,346 enrolled

Efficacy and Safety of Nirmatrelvir/Ritonavir for Treating Omicron Variant of COVID-19

Completed·XXiangao Jiang·N/A·NCT05813600·58 enrolled

Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial

Active, not recruiting·UUniversity of Melbourne·Phase 3·NCT04483960·2,200 enrolled

Effectiveness and Safety of New Oral Antivirals for COVID-19

Unknown status·UUniversidade do Porto··NCT05894603·211 enrolled

Open Multicentre Study of the Safety and Efficacy Against COVID-19 of Nirmatrelvir/Ritonavir in the Adult Population

Completed·PPromomed, LLC·Phase 3·NCT05601167·264 enrolled

Non-inferiority Trial on Treatments in Early COVID-19

Completed·AAzienda Ospedaliera Universitaria Integrata Verona·Phase 3·NCT05321394·536 enrolled

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT05261139·160 enrolled

A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19

Terminated· Pfizer logo

Pfizer·Phase 1·NCT05386472·25 enrolled

A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System

Completed· Pfizer logo

Pfizer·Phase 2·NCT05438602·158 enrolled

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19

Withdrawn· Pfizer logo

Pfizer·Phase 2·NCT05545319

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

Recruiting·UUniversity of Oxford·Phase 2·NCT05041907·3,800 enrolled

A REAL-WORLD STUDY ON THE EFFECTIVENESS OF NIRMATRELVIR-RITONAVIR IN REDUCING SEVERE OUTCOMES FROM COVID-19

Completed· Pfizer logo

Pfizer··NCT07261085·99,000 enrolled

ART2 trials

Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants

Completed· Pfizer logo

Pfizer·Phase 1·NCT05525910·15 enrolled

A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants

Withdrawn· Pfizer logo

Pfizer·Phase 1·NCT06397144

Long COVID-191 trial

PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway

Active, not recruiting·HHaukeland University Hospital·Phase 3·NCT05852873·2,000 enrolled

Complication1 trial

Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac Surgery

Unknown status·CChina National Center for Cardiovascular Diseases·Phase 4·NCT05690646·491 enrolled

CAR1 trial

A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.

Completed· Pfizer logo

Pfizer··NCT07090486·14,000 enrolled

11 more indications

Outcome1 trial

Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir

Completed·—··NCT05624840·85 enrolled

TED1 trial

Bioequivalence Study of Nirmatrelvir & Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus Paxlovid 150 + 100 mg Film Coated Tablets (Pfizer Europe, Belgium)

Completed·GGenuine Research Center, Egypt·Phase 1·NCT05491330·28 enrolled

Oral1 trial

Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.

Completed· Pfizer logo

Pfizer·Phase 1·NCT05544786·12 enrolled

Hospitalized Patients1 trial

Appropriate Evaluation of Antiviral Therapy With Nirmatrelvir-ritonavir in Hospitalized Patients

Unknown status·FFirst People's Hospital of Hangzhou··NCT05749445·200 enrolled

Statin1 trial

A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin

Completed· Pfizer logo

Pfizer·Phase 1·NCT05898672·12 enrolled

Quality of Life1 trial

ImPROving Quality of LIFe in the Long COVID Patient

Completed·KKarolinska Institutet·Phase 2·NCT05823896·219 enrolled

Chronic Kidney Disease1 trial

Efficiency and Safety of Paxlovid for COVID-19 Patients With Severe Chronic Kidney Disease

Unknown status·—·Phase 4·NCT05938140·30 enrolled

Pneumonia1 trial

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting·UUMC Utrecht·Phase 3·NCT02735707·20,000 enrolled

Long COVID1 trial

Paxlovid for Treatment of Long Covid

Completed·SStanford University·Phase 2·NCT05576662·168 enrolled

Efficacy and Safety1 trial

A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.

Completed·HHarlan M Krumholz·Phase 2·NCT05668091·100 enrolled

Women1 trial

A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating Women

Completed· Pfizer logo

Pfizer·Phase 1·NCT05441215·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 38 trial records for Nirmatrelvir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nirmatrelvir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nirmatrelvir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: SARS Coronavirus 3c-Like Proteinase Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Pfizer

Paxlovid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2027

Q2 2027

Q1 2028

Trials by Indication[1]

COVID-1922 trials

ART2 trials

Long COVID-191 trial

Complication1 trial

CAR1 trial

Outcome1 trial

TED1 trial

Oral1 trial

Hospitalized Patients1 trial

Statin1 trial

Quality of Life1 trial

Chronic Kidney Disease1 trial

Pneumonia1 trial

Long COVID1 trial

Efficacy and Safety1 trial

Women1 trial

References

Drug Info

Quick Facts

Related News